Syndax Pharmaceuticals Inc. (SNDX) has disclosed a new risk, in the Accounting & Financial Operations category.
Syndax Pharmaceuticals Inc. faces a significant business risk due to its limited experience in generating revenue from product sales, particularly with its key products, Revuforj and Niktimvo. The company’s success is contingent upon obtaining necessary regulatory approvals and effectively commercializing these products, as well as future ones like revumenib and axatilimab. Challenges such as limited commercialization expertise, potential ineffectiveness, side effects, and competitive pressures could hinder their market presence. Additionally, the ability to establish robust manufacturing processes, secure patient access, and maintain intellectual property rights will be critical in mitigating this risk and achieving substantial revenue growth.
Overall, Wall Street has a Strong Buy consensus rating on SNDX stock based on 10 Buys and 1 Hold.
To learn more about Syndax Pharmaceuticals Inc.’s risk factors, click here.